Arcus Biosciences (RCUS) traded lower in the premarket on Monday after the oncology-focused biotech announced the discontinuation of a late-stage trial designed to evaluate its anti-TIGIT therapy ...

Arcus Biosciences is discontinuing a phase 3 lung cancer trial it was conducting with Gilead Sciences. Arcus, an oncology company, said Monday it was ending the trial due to futility, meaning it doesn ...

Add Outdoor Life (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results. A ...

You want that new video game so badly, but you’re trying to knock your credit card balance down. Or you’re binging your favorite TV show and can’t wait to find out if a character lives, but it’s late, ...

Arcus Biosciences posted strong FY25 results, beating EPS and revenue estimates despite no commercial products and heavy R&D investment. RCUS’s valuation premium is driven by Casdatifan, a ...

At least two additional data presentations for casdatifan are expected in 2026: updated data for casdatifan plus cabozantinib and initial data in early-line kidney cancer In addition to the ongoing ...

ACE advises: For many Maine small businesses, climate change can feel abstract — until a storm disrupts operations, energy costs spike or insurance premiums rise. The good news is that many ...

Ratings for Arcus Biosciences (NYSE:RCUS) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, ...

Arcus Infrastructure Partners will acquire Wifinity, a UK-based internet managed services provider, from LDC and Literacy Capital. Literacy will generate a total expected return of 5.2x MoM, in line ...

Rochdale, England-based WCCTV was formed in 2001 Arcus’ investment will be made via Arcus European Infrastructure Fund 4 SCSp LDC initially invested in WCCTV in 2021 LDC will exit its investment in ...